Эффективность инфликсимаба у больной с неблагоприятным течением ювенильного ревматоидного артрита
Аннотация
Ключевые слова: дети, ранний ювенильный ревматоидный артрит, инфликсимаб, лечение.
Об авторах
Л.А. БалыковаН.В. Ивянская
Т.И. Корнилова
А.В. Балыкова
Список литературы
1. Cassidy J.T., Petty R.E., Laxer R.M., Lindsley C.B. Textbook of Pediatric Rheumatology 5th ed. Philadelphia: W.B. Saunders. 2005.
2. Foster H.E., Marshall N., Myers A. et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003; 48: 767–775.
3. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001; 344: 907–916.
4. Emery P., Seto Y. Role of biologics in early arthritis. Clin. Exp. Rheumatol. 2003; 21 (suppl. 31): 191–194.
5. Combe B. Progression in early rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol. 2009; 23 (1): 59–69.
6. Dawidowicz K., Allanore Y., Guedj M. et al. The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype. Ann. Rheum. Dis. 2011; 70: 117–122.
7. Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann. Rheum. Dis. 2003; 62 (Suppl. 2): 112–119.
8. Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59: 762–784.
9. Vastesaeger N., Xu S., Aletaha D. et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology. 2009; 48 (9): 1114–1121.
10. Visser K., Goekoop–Ruiterman Y.P., de Vries-Bouwstra J.K. et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the Best study. Ann. Rheum. Dis. 2010; 69 (7): 1333–1337.
11. Emery P., Mclnnes I.B., van Vollenhoven R., Kraan M.C. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology. 2008; 47 (4): 392–398.
12. Maradit-Kremers H., Crowson C.S., Nicola P.J. et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis. A population based controlled study. Arthritis Rheum. 2005; 52: 722–732.
13. Chung C. P., Avalos I., Raggi P. Atherosclerosis inflammation: Insights from rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (8): 1228–1233.
14. Tam L.S., Tomlinson B., Chu T.T. et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (9): 1495–1498.
15. Goodson N., Marks J., Lunt M. et аl. Cardiovascular admissions and morality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Arthritis Rheum. 2005; 46: 2010–2019.
16. Гудкова Е.Ю., Алексеева Е.И. Факторы риска раннего развития кардиоваскулярной патологии у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2007; 6 (5): 74–79.
17. Kitas G.D., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann. Rheum. Dis. 2011; 70: 8–14.
18. Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей. Качество жизни. Медицина. 2008; 1: 14–17.
19. Askermann C., Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Tartets. 2007; 11: 1369–1384.
20. Насонов Е.Л. Фактор некроза опухоли ― новая мишень для противовоспалительной терапии ревматоидного артрита. Русский медицинский журнал. 2000; 8 (17): 718–722.
21. Lipsky P., Heijde van der D., Clair E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New. Engl. J. Med. 2000; 343: 1594–1602.
22. Тakeuchi T., Yamanaka H., Inoue E. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM–2J). Mod. Rheumatol. 2008; 18 (5): 447–454.
23. Smolen J.S., Han C., van der Heijde D.M. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 2009; 68 (6): 823–827.
24. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.
25. Scarazatti M., Beltramelli M., Dell’Era L. et al. Infliximab in juvenile idiopathic arthritis. Ann. Rheum. Dis. 2001; 60: 1117–1152.
26. Gerloni V., Pontikaki I., Gattinara M. et al. Efficacy of repeated intravenous infusions of an anti-TNF-α monoclonal antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis. Results of an open label prospective study. Arthritis Rheum. 2005; 52 (2): 548–553.
27. Chaturvedi V.P. Pilot study of chimeric monoclonal anti-tumor necrosis factor alpha anti-body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis. American College of Rheumatology 66th Annual Scientific Meeting, October 24–25, 2002. New Orleans. Abstract 1272.
28. Honkanen V.E., Tynjala P., Vahasalo P. et al. Infliximab in juvenile arthritis: 1-year follow-up. American College of Rheumatology 66th Annual Scientific Meeting, October 24–25 2002. New Orleans. Abstract 1272.
29. Vinje O., Obiora E., Forre O. Juvenile chronic polyarthritis treated with infliximab. Ann. Rheum. Dis. 2000; 59: 713–749. Abstract 1125.
30. Masatlioglu S., Gogus F., Cevirgen D. et al. Infliximab in the treatment of refractory juvenile idiopathic arthritis. Arthritis Rheum. 2002; 46: 481. Abstract 1276.
31. Levalampi T., Honkanen V., Lahdenne P. et al. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis Scand. J. Rheumatol. 2007; 36: 189–193.
32. Russo R.A., Katsicas M.M. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J. Rheumatol. 2009; 36 (5): 1078–1082.
33. Pontikaki I., Gerloni V., Gattinara M. et al. Efficacy and safety of TNFα blockade in systemic JIA (SOJIA) compared to other JIA ILAR categories. Results of an open monocentric long-term prospective study of 155 patients. European League Against Rheumatism, June 21–24, 2006. Amsterdam, Netherlands. Abstract SAT0384.
34. Tynjälä P., Vähäsalo P., Honkanen V., Lahdenne P. Drug survival of the first and second course of anti-TNF agents in juvenile idiopathic arthritis. Ann. Rheum. Dis. 2009; 68 (4): 552–557.
35. Никишина И.П., Родионовская С.Р., Шаповаленко А.Н. и др. Инфликсимаб в терапии рефрактерных вариантов ювенильного артрита. Вопросы современной педиатрии. 2010; 9 (1): 142–149.
36. Вахлярская С.С., Кондратенко И.В., Бологов А.А. Инфликсимаб в терапии тяжелых форм ювенильного артрита у детей. Педиатрия. 2008; 2: 19–21.
37. Алексеева Е.И., Алексеева А.М., Валиева С.И. и др. Влияние инфликсимаба на динамику функционального класса и рентгенологические изменения хрящевой и костной ткани суставов у больных с различными вариантами ювенильного артрита. Вопросы современной педиатрии. 2008; 7 (4): 30–44.
38. Алексеева Е.И., Бзарова Т.М., Валиева С.И. и др. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7 (2): 22–29.
39. Ruperto N., Lovell D.J., Cuttica R. еt al. Long term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann. Rheum. Dis. 2010; 718 (69): 718–722.
40. Van der Kooij S.M., le Cessie S., Goekoop-Ruiterman Y.P. et al. Clinical and radiological efficacy of initial delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 2009; 68: 1153–1158.
41. Smolen J.S., van der Heijde D.M., Clair E.W. et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high dose methotrexate with or without concomitant in iximab: results from the ASPIRE trial. Arthritis Rheum. 2006; 54: 702–710.
42. Durez P., Malghem J., Nzeusseu Toukap A. et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007; 56: 3919–3927.
43. Takeuchi T. Indications for and use of biologics in early rheumatoid arthritis based on the evidence. Nippon Rinsho. 2009; 67 (5): 1043–1049.
44. Quinn M.A., Conaghan P.G., O’Connor et al. Very early treatment with infliximab in addition to methotrexate in early, poor prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005; 52 (1): 27–35.
45. Слепцова Т.В. Эффективность и безопасность ингибитора ФНО α ― инфликсимаба при раннем ювенильном ревматоидном артрите. Автореф. дис. …канд. мед. наук. М. 2011. С. 29.
46. Алексеева Е.И., Бзарова Т.М. Алгоритм диагностики и лечения ювенильного артрита. Вопросы современной педиатрии. 2010; 9 (6): 78–104.
47. Ferrante A., Parinello A.G., Avellone G. et al. Atherosclerosis in females patients with rheumatoid arthritis; a two years follow up. Ann. Rheum. Dis. 2005; 64 (suppl. 3): 91–98.
48. Wolfe F., Nadareishvili Z., Hallebeck J. et al. Antitumor necrosis factor therapy with infliximab decreases the risk of stroke in patients with rheumatoid arthritis. Arthr. Rheum. 2004; 50: 4099.
49. Askling J., Dixon W. Influence of biological agents on cardiovascular disease in rheumatoid arthritis. Ann. Rheum. Dis. 2011; 70 (4): 561–562.
Рецензия
Для цитирования:
Балыкова Л., Ивянская Н., Корнилова Т., Балыкова А. Эффективность инфликсимаба у больной с неблагоприятным течением ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2011;10(3):157–165.
For citation:
Balykova L., Ivyanskaya N., Kornilova T., Balykova A. EFFICACY OF INFLIXIMAB IN PATIENT WITH UNFAVORABLE CLINICAL COURSE OF JUVENILE RHEUMATOID ARTHRITIS. Current Pediatrics. 2011;10(3):157–165.
Послать статью по эл. почте 
